Advertisement

Topics

Just how good an investment is the biopharmaceutical sector?

07:00 EST 1st December 2017 | BioPortfolio

Summary of "Just how good an investment is the biopharmaceutical sector?"

Uncertainty surrounding the risk and reward of investments in biopharmaceutical companies poses a challenge to those interested in funding such enterprises. Using data on publicly traded stocks, we track the performance of 1,066 biopharmaceutical companies from 1930 to 2015-the most comprehensive financial analysis of this sector to date. Our systematic exploration of methods for distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate classification method. We find that the performance of the biotech sector is highly sensitive to the presence of a few outlier companies, and confirm that nearly all biotech companies are loss-making enterprises, exhibiting high stock volatility. In contrast, since 2000, pharmaceutical companies have become increasingly profitable, with risk-adjusted returns consistently outperforming the market. The performance of all biopharmaceutical companies is subject not only to factors arising from their drug pipelines (idiosyncratic risk), but also from general economic conditions (systematic risk). The risk associated with returns has profound implications both for patterns of investment and for funding innovation in biomedical R&D.

Affiliation

Journal Details

This article was published in the following journal.

Name: Nature biotechnology
ISSN: 1546-1696
Pages: 1149-1157

Links

DeepDyve research library

PubMed Articles [4962 Associated PubMed Articles listed on BioPortfolio]

The inherent risks associated with newly traded biopharmaceutical firms.

Here, we provide a comprehensive study related to the risks of all biopharmaceutical firms going public in the USA between 1996 and 2015. We found 355 firms that met our requirements for being in the ...

Banking for health: the role of financial sector actors in investing in global health.

The world faces multiple health financing challenges as the global health burden evolves. Countries have set an ambitious health policy agenda for the next 15 years with prioritisation of universal he...

Sustaining for-profit emergency healthcare services in low resource areas.

The Bawaskars in their Comment "Emergency care in rural settings: Can doctors be ethical and survive?" raise a context-specific question about the sustainability of emergency care in rural, low resour...

Technical quality of delivery care in private- and public-sector health facilities in Enugu and Lagos States, Nigeria.

Private-sector providers are increasingly being recognized as important contributors to the delivery of healthcare. Countries with high disease burdens and limited public-sector resources are consider...

Return on Investment Analysis of Breast Cancer Screening and Downstaging in Egypt: Implications for Developing Countries.

The aim of this study was to perform a return-on-investment (ROI) analysis of a breast cancer screening program in Egypt by comparing net profit in treatment costs saved to program cost investment.

Clinical Trials [1352 Associated Clinical Trials listed on BioPortfolio]

Food and Nutrition Education in Quilombolas Communities With Food Insecurity: Multi-sector Intervention

To optimize the food security in quilombolas communities with high prevalence of food insecurity and obesity, the present study proposes to test a multi-sector intervention including agric...

Effect of Public Sector Antiretroviral Treatment Programme on Tuberculosis and Immunization Care

A scale-up of public sector antiretroviral treatment (ART) programmes may divert scarce resources from other priority primary care programmes like tuberculosis and childhood immunization. ...

Determine Return on Investment in Heart Failure Remote Monitoring Program

The study will test a hypothesis that the remote monitoring with text and email alerts sent to study subject and optional family/other caregiver (Intervention 1) will have a higher return ...

Improving Depression Treatment for Older Minority Adults

The purpose of this study is to improve access to quality depression care for older, low-income, minority adults in public sector health care. The study will examine current depression car...

Evaluation of Essential Surgical Skills-Emergency Maternal and Child Health (ESS-EMCH) Training by Assessing the Doctors' Practices

The aim of the proposed study is to determine if specific training in management of general, obstetric, neonatal and pediatric emergencies results in a change in practice of doctors workin...

Medical and Biotech [MESH] Definitions

An organizational enterprise between a public sector agency, federal, state or local, and a private sector entity. Skills and assets of each sector are shared to deliver a service or facility for the benefit or use of the general public.

A component of the private sector characterized by ease of entry; reliance on indigenous resources; family ownership; small scale operations; skills acquired outside of the formal sector; and unregulated markets.

Economic sector concerned with the provision, distribution, and consumption of health care services and related products.

Guideline for determining when it is morally permissible to perform an action to pursue a good end with knowledge that the action will also bring about bad results. It generally states that, in cases where a contemplated action has such double effect, the action is permissible only if: it is not wrong in itself; the bad result is not intended; the good result is not a direct causal result of the bad result; and the good result is "proportionate to" the bad result. (from Solomon, "Double Effect," in Becker, The Encyclopedia of Ethics, 1992)

Material from which the casting mold is made in the fabrication of gold or cobalt-chromium castings. (Boucher's Clinical Dental Terminology, 4th ed, p168)

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...


Searches Linking to this Article